XENON PHARMACEUTICALS INC. Revenue from Contract with Customer, Excluding Assessed Tax
XENON PHARMACEUTICALS INC. (XENE) reported Revenue from Contract with Customer, Excluding Assessed Tax of $311.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-06.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2019-03-06
- XENON PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2017-12-31 was $16.00K.
- XENON PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2017-09-30 was $264.00K.
- XENON PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for fiscal 2017 was $311.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2017-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $280.00K derived: sum of 2 quarters · filed 2019-03-06 | $311.00K 10-K · filed 2019-03-06 | |
| 2017-09-30 | $264.00K 10-Q · filed 2018-11-06 | $295.00K 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |